[go: up one dir, main page]

SG11201701385WA - Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations - Google Patents

Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

Info

Publication number
SG11201701385WA
SG11201701385WA SG11201701385WA SG11201701385WA SG11201701385WA SG 11201701385W A SG11201701385W A SG 11201701385WA SG 11201701385W A SG11201701385W A SG 11201701385WA SG 11201701385W A SG11201701385W A SG 11201701385WA SG 11201701385W A SG11201701385W A SG 11201701385WA
Authority
SG
Singapore
Prior art keywords
nkg2a
vaccine combinations
nkg2b
antibody
nkg2b antibody
Prior art date
Application number
SG11201701385WA
Inventor
Der Burg Sjoerd Van
Hall Thorbald Van
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of SG11201701385WA publication Critical patent/SG11201701385WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201701385WA 2014-08-28 2015-08-28 Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations SG11201701385WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14182708 2014-08-28
PCT/NL2015/050600 WO2016032334A1 (en) 2014-08-28 2015-08-28 Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

Publications (1)

Publication Number Publication Date
SG11201701385WA true SG11201701385WA (en) 2017-03-30

Family

ID=51399587

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701385WA SG11201701385WA (en) 2014-08-28 2015-08-28 Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

Country Status (11)

Country Link
US (1) US20170253658A1 (en)
EP (1) EP3186282A1 (en)
JP (1) JP2017533255A (en)
KR (1) KR20170051462A (en)
CN (1) CN107106677A (en)
AU (1) AU2015307316A1 (en)
CA (1) CA2959318A1 (en)
IL (1) IL250623A0 (en)
RU (1) RU2017105425A (en)
SG (1) SG11201701385WA (en)
WO (1) WO2016032334A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011219715B2 (en) 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
CN103635487B (en) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 Selective elimination of erosive cells
US10711063B2 (en) 2014-09-16 2020-07-14 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR20240141862A (en) 2014-09-16 2024-09-27 이나뜨 파르마 에스.에이. Treatment regimens using anti-nkg2a antibodies
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3868787A1 (en) 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112019013282A2 (en) * 2016-12-30 2019-12-17 Celularity Inc genetically modified natural killer cells
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multispecific binding proteins for activation of NATURAL KILLER CELLS and their medical uses for cancer treatment
FI3582806T3 (en) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc HER2, NKG2D AND CD16 BINDING PROTEINS
DE102017001875A1 (en) * 2017-02-27 2018-08-30 Wolfgang Würfel Drug for malignant treatment
CN110891974B (en) 2017-05-12 2021-08-06 哈普恩治疗公司 mesothelin binding protein
SG10202102251YA (en) * 2017-08-16 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
CR20200196A (en) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc TRISPECIFIC PROTEINS AND METHODS OF USE
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
KR20200118824A (en) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. Combination therapy for cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (en) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Multispecific binding proteins that bind to CD33, NKG2D, and CD16, and methods of use thereof
EP3765508A1 (en) 2018-03-13 2021-01-20 Innate Pharma Treatment of head and neck cancer
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN112203691A (en) * 2018-05-15 2021-01-08 免疫医疗有限公司 cancer treatment
MA53284A (en) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN BINDING PROTEINS
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US12534526B2 (en) * 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
AU2019380307B2 (en) 2018-11-16 2026-01-29 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN110575537A (en) * 2019-09-06 2019-12-17 刘慧宁 Composition of DC vaccine and NKG2A antagonist and application of composition in resisting breast cancer or liver cancer
CN111303296B (en) * 2019-12-16 2021-01-29 启辰生生物科技(珠海)有限公司 Bifunctional fusion polypeptides, cells, pharmaceutical compositions and uses
AR122018A1 (en) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc NKG2D, CD16 AND CLEC12A BINDING PROTEINS
JP2023532768A (en) 2020-07-07 2023-07-31 バイオエヌテック エスエー RNA for treatment of HPV-positive cancer
MX2023002326A (en) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Cell localization signature and immunotherapy.
EP4221752A4 (en) * 2020-09-30 2024-12-04 Dren Bio, Inc. ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
CN116368154A (en) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 trispecific binder
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
MX2023007650A (en) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Subcutaneous administration of pd1/pd-l1 antibodies.
HRP20250628T1 (en) 2020-12-28 2025-07-18 Bristol-Myers Squibb Company MIXTURES OF ANTIBODIES AND METHODS OF USING THEM
WO2022179620A1 (en) * 2021-02-25 2022-09-01 克莱格医学有限公司 Cd94 engineered cell and composition thereof
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2024525758A (en) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア Multispecific binding agents to CD40 and CD137 in combination therapy for cancer - Patents.com
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
JP2025500845A (en) * 2021-12-14 2025-01-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Molecules that bind to CD94/NKG2A heterodimer polypeptides
US20250101113A1 (en) * 2022-01-11 2025-03-27 Board Of Regents, The University Of Texas System Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
CN116178552B (en) * 2022-12-30 2025-03-07 合肥天港免疫药物有限公司 Anti-CD94 antibodies and their applications
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (en) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3332A1 (en) * 2000-03-31 2001-10-11 Purdue Research Foundation TREATMENT METHOD USING LIGAND-IMMUNOGENIC CONJUGATES
US8993319B2 (en) * 2004-12-28 2015-03-31 Innate Pharma S.A. Monoclonal antibodies against NKG2A
DK2038306T3 (en) * 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
WO2008109852A2 (en) * 2007-03-07 2008-09-12 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
EP2062592A1 (en) * 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System for delivery into a XCR1 positive cell and uses thereof
BRPI0908508A2 (en) 2008-01-24 2016-03-22 Novo Nordisk As humanized anti-human nkg2a monoclonal antibody

Also Published As

Publication number Publication date
US20170253658A1 (en) 2017-09-07
RU2017105425A3 (en) 2019-03-20
KR20170051462A (en) 2017-05-11
CA2959318A1 (en) 2016-03-03
CN107106677A (en) 2017-08-29
RU2017105425A (en) 2018-09-28
IL250623A0 (en) 2017-04-30
EP3186282A1 (en) 2017-07-05
AU2015307316A8 (en) 2017-03-30
JP2017533255A (en) 2017-11-09
WO2016032334A1 (en) 2016-03-03
AU2015307316A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
IL250623A0 (en) Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
IL320713A (en) Antibodies, uses and methods
IL317989A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
ZA201704117B (en) Cd47 antibodies, methods, and uses
ZA201704467B (en) Anti-cd47 antibodies and uses thereof
ZA201701168B (en) Antibodies, compositions, and uses
IL252804B (en) Anti-c10orf54 antibodies and uses thereof
IL251248A0 (en) Anti-interleukin-33 antibodies and uses thereof
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
IL252929A0 (en) Humanized anti-acth antibodies and use thereof
EP3200823A4 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
IL247315A0 (en) Anti-acth antibodies and use thereof
IL252430A0 (en) Antibodies, uses and methods
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL247100A0 (en) Anti cd84 antibodies, compositions comprising same and uses thereof
GB201618515D0 (en) Combinations comprising antibodies, uses and methods